gentamicin has been researched along with Critical Illness in 48 studies
Gentamicins: A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.
Critical Illness: A disease or state in which death is possible or imminent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sixty-three ICU patients (Simplified Acute Physiology Score II = 43 ± 16) with severe sepsis and an indication for intravenous amikacin (n = 47) or gentamicin (n = 16) were included." | 7.83 | Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis. ( Allaouchiche, B; Evrard, A; Friggeri, A; Knani, H; Lavigne, JP; Lefrant, JY; Louart, B; Muller, L; Nucci, B; Roberts, JA; Roger, C, 2016) |
| "The objective of the present prospective pharmacokinetic study was to describe the variability of plasma gentamicin concentrations in critically ill patients with acute kidney injury (AKI) necessitating extended daily diafiltration (EDD-f) using a population pharmacokinetic model and to subsequently perform Monte Carlo dosing simulations to determine which dose regimen achieves the pharmacodynamic targets the most consistently." | 7.76 | Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury. ( Field, J; Kirkpatrick, CM; Lipman, J; Roberts, JA; Tallot, M; Visser, A; Whitbread, R, 2010) |
| "Once-daily gentamicin therapy is becoming increasingly common in pediatric practice; however, little is known about pharmacokinetics in critical illness." | 7.76 | Extended-interval gentamicin: population pharmacokinetics in pediatric critical illness. ( Durward, A; Lopez, SA; Mulla, H; Tibby, SM, 2010) |
| "The incidence of gentamicin-associated acute kidney injury (AKI) as defined by the RIFLE criteria is unknown." | 7.75 | Gentamicin-associated acute kidney injury. ( Fluck, RJ; Kolhe, NV; Selby, NM; Shaw, S; Woodier, N, 2009) |
| "Acute kidney injury is an accompanying manifestation of sepsis/septic shock leading to worsening of morbidity and also mortality and requiring use of intermittent or continual renal replacement therapy." | 6.48 | [An effect of continuous and intermittent renal replacement therapy on antibiotic treatment in critically ill patients with sepsis - a practice-based perspective of vancomycin and gentamycin therapies]. ( Duricová, J; Grundmann, M; Kacířová, I; Martínek, A; Petejová, N; Plášek, J; Valkovský, I; Zahálková, J, 2012) |
| "Sixty-three ICU patients (Simplified Acute Physiology Score II = 43 ± 16) with severe sepsis and an indication for intravenous amikacin (n = 47) or gentamicin (n = 16) were included." | 3.83 | Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis. ( Allaouchiche, B; Evrard, A; Friggeri, A; Knani, H; Lavigne, JP; Lefrant, JY; Louart, B; Muller, L; Nucci, B; Roberts, JA; Roger, C, 2016) |
| "Term neonates with unrepaired CHD who received gentamicin for empiric treatment of sepsis were identified over a 3-year period." | 3.78 | Use of 4-mg/kg/24-hour empiric aminoglycoside dosing in preoperative neonates with congenital heart disease. ( Moffett, BS; Rossano, JW, 2012) |
| "Current dosing recommendations for administration of gentamicin to septic patients with acute kidney injury (AKI) on continuous venovenous hemofiltration (CVVH) at a filtration rate of 45 ml/kg/h are missing." | 3.78 | Gentamicin pharmacokinetics during continuous venovenous hemofiltration in critically ill septic patients. ( Brozmanova, H; Duricova, J; Grundmann, M; Kacirova, I; Martinek, A; Petejova, N; Urbanek, K; Zahalkova, J, 2012) |
| "To characterize the extent that serum gentamicin concentrations are associated with hearing loss indicated by otoacoustic emission (OAE) screen failure in critically ill neonates receiving gentamicin in accordance with a high-dose, extended-interval dosing protocol." | 3.77 | Otoacoustic emission screen results in critically ill neonates who received gentamicin in the first week of life. ( Commers, AR; Cooper, AC; Finkelstein, M; Hoff, DS; Lipnik, PG; Tollefson, LM; Wilcox, RA, 2011) |
| "The initial dose of gentamicin 4 mg/kg for these critically ill premature and mature neonates with sepsis during the first week of life was high enough to reach bactericidal C(max,1) within 6-10 mg/L." | 3.76 | Tolerability and outcomes of kinetically guided therapy with gentamicin in critically ill neonates during the first week of life: an open-label, prospective study. ( Chládek, J; Chládková, J; Martínková, J; Pokorná, P; Selke-Krulichová, I; Vobruba, V; Záhora, J, 2010) |
| "The objective of the present prospective pharmacokinetic study was to describe the variability of plasma gentamicin concentrations in critically ill patients with acute kidney injury (AKI) necessitating extended daily diafiltration (EDD-f) using a population pharmacokinetic model and to subsequently perform Monte Carlo dosing simulations to determine which dose regimen achieves the pharmacodynamic targets the most consistently." | 3.76 | Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury. ( Field, J; Kirkpatrick, CM; Lipman, J; Roberts, JA; Tallot, M; Visser, A; Whitbread, R, 2010) |
| "The incidence of gentamicin-associated acute kidney injury (AKI) as defined by the RIFLE criteria is unknown." | 3.75 | Gentamicin-associated acute kidney injury. ( Fluck, RJ; Kolhe, NV; Selby, NM; Shaw, S; Woodier, N, 2009) |
| "Seventy-seven critically ill patients treated with gentamicin for gram-negative sepsis were included." | 3.70 | Factors affecting gentamicin pharmacokinetics in septic patients. ( Kong, CW; Lee, TY; Lin, BS; Tang, GJ; Tang, JJ, 1999) |
| " In this period, several new population pharmacokinetic studies have focused on these subpopulations, providing insights into the typical values of the most relevant pharmacokinetic parameters, the variability of these parameters and possible explanations for this variability, although unexplained variability often remains high." | 2.82 | Clinical Pharmacokinetics of Gentamicin in Various Patient Populations and Consequences for Optimal Dosing for Gram-Negative Infections: An Updated Review. ( de Vroom, SL; Hodiamont, CJ; Mathôt, RAA; Prins, JM; van den Broek, AK; van Hest, RM, 2022) |
| " Gentamicin pharmacokinetic parameters were estimated by non-linear regression analysis, assuming a one-compartment model and first-order elimination from the central compartment." | 2.68 | Expanded gentamicin volume of distribution in critically ill adult patients receiving total parenteral nutrition. ( Abad, J; Jiménez, NV; Ordovás, JP; Ronchera-Oms, CL; Tormo, C, 1995) |
| "Acute kidney injury is an accompanying manifestation of sepsis/septic shock leading to worsening of morbidity and also mortality and requiring use of intermittent or continual renal replacement therapy." | 2.48 | [An effect of continuous and intermittent renal replacement therapy on antibiotic treatment in critically ill patients with sepsis - a practice-based perspective of vancomycin and gentamycin therapies]. ( Duricová, J; Grundmann, M; Kacířová, I; Martínek, A; Petejová, N; Plášek, J; Valkovský, I; Zahálková, J, 2012) |
| " A once-daily dosage regimen has replaced multiple dosing of gentamicin in most intensive care units." | 2.41 | Gentamicin dosing in critically ill patients. ( Bonde, J; Christrup, LL; Hansen, M; Jarløv, JO; Kampmann, JP, 2001) |
| " For aminoglycosides, we recommend extended interval dosing and initiating Seraph 100 at least 30 min to 1 h after completion of infusion to avoid the possibility of interference with maximum concentrations." | 1.91 | Hemoperfusion with Seraph 100 Microbind Affinity Blood Filter Unlikely to Require Increased Antibiotic Dosing: A Simulations Study Using a Pharmacokinetic/Pharmacodynamic Approach. ( Chung, KK; DeLuca, JP; Kress, AT; Reed, T; Selig, DJ; Stewart, IJ, 2023) |
| "Amikacin was not commonly used in Quebec." | 1.72 | Aminoglycosides' dosing and monitoring practices in critically ill patients in Quebec hospitals. ( Duong, A; Marsot, A; Simard, C; Thirion, DJG; Williamson, D, 2022) |
| " The first therapeutic drug monitoring concentration for each patient was collected, as was clinical and dosing information." | 1.56 | External Validation of Model-Based Dosing Guidelines for Vancomycin, Gentamicin, and Tobramycin in Critically Ill Neonates and Children: A Pragmatic Two-Center Study. ( de Hoop, M; de Wildt, SN; Hartman, SJF; Orriëns, LB; Poel, T; Zwaag, SM, 2020) |
| " The demographic characteristics, dosage regimen and gentamicin concentrations were recorded for each neonate." | 1.56 | Dose Optimization of Gentamicin in Critically Ill Neonates. ( Al Jufairi, M; Elsegai, OAM; Qader, AM; Sridharan, K, 2020) |
| "In sub-Saharan Africa (SSA), gentamicin is commonly used for severe infections in non-intensive-care-unit (ICU) settings, but pharmacokinetic and pharmacodynamic data for this specific population are lacking." | 1.51 | Population Pharmacokinetics with Monte Carlo Simulations of Gentamicin in a Population of Severely Ill Adult Patients from Sub-Saharan Africa. ( Beirão, JC; Bos, JC; Lang, CN; Mathôt, RAA; Mistício, MC; Nunguiane, G; Prins, JM; van Hest, RM, 2019) |
| "Optimal dosing for nebulized gentamicin is unknown." | 1.48 | Pharmacokinetics of intravenous and nebulized gentamicin in critically ill patients. ( Adier, C; Boisson, M; Couet, W; Grégoire, N; Hadzic, M; Marchand, S; Mimoz, O, 2018) |
| "External validation of population pharmacokinetic (PK) models is warranted before they can be clinically applied to aid in antibiotic dose selection." | 1.48 | Predictive performance of a gentamicin population pharmacokinetic model in two western populations of critically ill patients. ( Bukkems, LH; Hodiamont, CJ; Juffermans, NP; Lefrant, JY; Roberts, JA; Roger, C; van Hest, RM, 2018) |
| " The aim of this study was to evaluate the effect of gentamicin dosing based on Cmax after the first dose on gentamicin target attainment in critically ill patients." | 1.46 | Therapeutic Drug Monitoring of Gentamicin Peak Concentrations in Critically Ill Patients. ( de Jong, MD; Hodiamont, CJ; Janssen, JM; Juffermans, NP; Mathôt, RA; van Hest, RM, 2017) |
| " The risk of toxicity is reduced by extended-interval dosing of aminoglycosides, defined as 5 - 7 mg/kg given intravenously in intervals of 24 hours or greater based on serum drug concentrations." | 1.42 | Variable pharmacokinetics of extended interval tobramycin or gentamicin among critically ill patients undergoing continuous venovenous hemofiltration. ( Barns, B; Block, C; Burrill, S; Chuk, AC; Fu, J; Katrych, O; Kousar, N; Lahey, T; Rickrode, G; Saeed, F; Saunders-Hao, P, 2015) |
| " In the 50 remaining patients, a change in dosing was performed in 14 patients, leading adequate peak plasma level in 2 patients." | 1.42 | Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations. ( Aubert, C; Barbar, S; Bastide, S; Elotmani, L; Lefrant, JY; Lloret, S; Molinari, N; Muller, L; Nucci, B; Polge, A; Pradel, G; Roberts, JA; Roger, C; Saissi, G, 2015) |
| "To determine dose and eligibility criteria for once-daily dosing (ODD) of gentamicin in critically ill pediatric patients." | 1.40 | Dose derivation of once-daily dosing guidelines for gentamicin in critically ill pediatric patients. ( Atenafu, EG; Bitnun, SA; Cox, P; Papaioannou, V; Parshuram, C; Pong, S; Richardson, S; Schwartz, S; Seto, W; Trope, A; Zakova, M, 2014) |
| "Gentamicin is a widely used antibiotic in the intensive care unit (ICU)." | 1.39 | Gentamicin in hemodialyzed critical care patients: early dialysis after administration of a high dose should be considered. ( Badin, J; Dupuis, A; Pinsard, M; Robert, R; Veinstein, A; Venisse, N, 2013) |
| " We studied gentamicin pharmacokinetic data from patients treated between January 2006 and June 2008 in two intensive-care units." | 1.36 | Pharmacokinetics of gentamicin in critically ill patients: pilot study evaluating the first dose. ( Gonçalves-Pereira, J; Martins, A; Póvoa, P, 2010) |
| "To determine the pharmacokinetic outcomes of a simplified, weight-based, extended-interval gentamicin dosing protocol for critically ill neonates." | 1.35 | Pharmacokinetic outcomes of a simplified, weight-based, extended-interval gentamicin dosing protocol in critically ill neonates. ( Commers, AR; Hoff, DS; Lipnik, PG; Liu, M; Tollefson, LM; Wilcox, RA, 2009) |
| " Based on these data, the majority of critically ill patients would not be predicted to achieve the PD target under current dosing regimens." | 1.35 | Suboptimal aminoglycoside dosing in critically ill patients. ( Bies, R; Bigos, KL; Capitano, B; Lee, H; Rea, RS; Smith, R, 2008) |
| " Full-term infants receiving HFOV should be initiated at gentamicin dosing intervals of 18 hours rather than the traditional 12 hours recommended for this age group." | 1.32 | Gentamicin pharmacokinetics in term newborn infants receiving high-frequency oscillatory ventilation or conventional mechanical ventilation: a case-controlled study. ( Bhatt-Mehta, V; Donn, SM, 2003) |
| " However, the pharmacokinetic parameters are variable in these patients." | 1.31 | Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens. ( Barletta, JF; Erstad, BL; Johnson, SB; Nix, DE; Nix, LC, 2000) |
| " The main objective of this pharmacokinetic observational study was to determine the adequacy of a 3 mg/kg loading dose of gentamicin or tobramycin in attaining an initial peak level of 8 micrograms/ml or greater." | 1.30 | Impact of altered aminoglycoside volume of distribution on the adequacy of a three milligram per kilogram loading dose. Critical Care Research Group. ( Dorman, T; Lipsett, PA; Swoboda, S; Trentler, B; Zarfeshenfard, F, 1998) |
| "This investigation compares the accuracy of calculating gentamicin pharmacokinetic parameters by a noninvasive body composition technique (bioelectrical impedance analysis; BIA) with an empiric method, against the two-point method as the criterion standard." | 1.29 | Determination of gentamicin pharmacokinetics by bioelectrical impedance in critically ill adults. ( Horst, HM; Mlynarek, M; Peterson, EL; Robert, S; Zarowitz, BJ, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (12.50) | 18.2507 |
| 2000's | 9 (18.75) | 29.6817 |
| 2010's | 27 (56.25) | 24.3611 |
| 2020's | 6 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Duong, A | 1 |
| Thirion, DJG | 1 |
| Williamson, D | 1 |
| Simard, C | 1 |
| Marsot, A | 1 |
| Selig, DJ | 1 |
| Reed, T | 1 |
| Chung, KK | 1 |
| Kress, AT | 1 |
| Stewart, IJ | 1 |
| DeLuca, JP | 1 |
| Hodiamont, CJ | 4 |
| van den Broek, AK | 1 |
| de Vroom, SL | 1 |
| Prins, JM | 2 |
| Mathôt, RAA | 2 |
| van Hest, RM | 6 |
| Sridharan, K | 1 |
| Al Jufairi, M | 1 |
| Qader, AM | 1 |
| Elsegai, OAM | 1 |
| Flint, RB | 1 |
| Allegaert, K | 1 |
| Hartman, SJF | 1 |
| Orriëns, LB | 1 |
| Zwaag, SM | 1 |
| Poel, T | 1 |
| de Hoop, M | 1 |
| de Wildt, SN | 1 |
| Zavascki, AP | 1 |
| Klee, BO | 1 |
| Bulitta, JB | 1 |
| Janssen, JM | 1 |
| de Jong, MD | 2 |
| Mathôt, RA | 2 |
| Juffermans, NP | 3 |
| Bukkems, LH | 1 |
| Roger, C | 3 |
| Lefrant, JY | 3 |
| Roberts, JA | 5 |
| Boisson, M | 1 |
| Mimoz, O | 1 |
| Hadzic, M | 1 |
| Marchand, S | 1 |
| Adier, C | 1 |
| Couet, W | 1 |
| Grégoire, N | 1 |
| Bos, JC | 1 |
| Mistício, MC | 1 |
| Nunguiane, G | 1 |
| Lang, CN | 1 |
| Beirão, JC | 1 |
| Zakova, M | 1 |
| Pong, S | 1 |
| Trope, A | 1 |
| Atenafu, EG | 1 |
| Papaioannou, V | 1 |
| Bitnun, SA | 1 |
| Richardson, S | 1 |
| Schwartz, S | 1 |
| Cox, P | 1 |
| Parshuram, C | 1 |
| Seto, W | 1 |
| D'Arcy, DM | 1 |
| Corrigan, OI | 1 |
| Deasy, E | 1 |
| Gowing, CM | 1 |
| Donnelly, MB | 1 |
| Wieske, L | 1 |
| Witteveen, E | 1 |
| Verhamme, C | 1 |
| Schultz, MJ | 1 |
| van Schaik, IN | 1 |
| Horn, J | 1 |
| Nucci, B | 2 |
| Molinari, N | 1 |
| Bastide, S | 1 |
| Saissi, G | 1 |
| Pradel, G | 1 |
| Barbar, S | 1 |
| Aubert, C | 1 |
| Lloret, S | 1 |
| Elotmani, L | 1 |
| Polge, A | 1 |
| Muller, L | 2 |
| Chuk, AC | 1 |
| Saeed, F | 1 |
| Kousar, N | 1 |
| Burrill, S | 1 |
| Barns, B | 1 |
| Rickrode, G | 1 |
| Fu, J | 1 |
| Katrych, O | 1 |
| Saunders-Hao, P | 1 |
| Block, C | 1 |
| Lahey, T | 1 |
| Louart, B | 1 |
| Friggeri, A | 1 |
| Knani, H | 1 |
| Evrard, A | 1 |
| Lavigne, JP | 1 |
| Allaouchiche, B | 1 |
| Shekar, K | 1 |
| Barnett, AG | 1 |
| Diab, S | 1 |
| Wallis, SC | 1 |
| Fung, YL | 1 |
| Fraser, JF | 1 |
| Ereshefsky, BJ | 1 |
| Al-Hasan, MN | 1 |
| Gokun, Y | 1 |
| Martin, CA | 1 |
| Del Bono, V | 1 |
| Giacobbe, DR | 1 |
| Marchese, A | 1 |
| Parisini, A | 1 |
| Fucile, C | 1 |
| Coppo, E | 1 |
| Marini, V | 1 |
| Arena, A | 1 |
| Molin, A | 1 |
| Martelli, A | 1 |
| Gratarola, A | 1 |
| Viscoli, C | 1 |
| Pelosi, P | 1 |
| Mattioli, F | 1 |
| Slater, MB | 1 |
| Gruneir, A | 1 |
| Rochon, PA | 1 |
| Howard, AW | 1 |
| Koren, G | 1 |
| Parshuram, CS | 1 |
| Ingelfinger, JR | 1 |
| Bouman, CS | 1 |
| Rea, RS | 1 |
| Capitano, B | 1 |
| Bies, R | 1 |
| Bigos, KL | 1 |
| Smith, R | 1 |
| Lee, H | 1 |
| Lopez, SA | 1 |
| Mulla, H | 1 |
| Durward, A | 1 |
| Tibby, SM | 1 |
| Selby, NM | 1 |
| Shaw, S | 1 |
| Woodier, N | 1 |
| Fluck, RJ | 1 |
| Kolhe, NV | 1 |
| Gonçalves-Pereira, J | 1 |
| Martins, A | 1 |
| Póvoa, P | 1 |
| Hoff, DS | 2 |
| Wilcox, RA | 2 |
| Tollefson, LM | 2 |
| Lipnik, PG | 2 |
| Commers, AR | 2 |
| Liu, M | 1 |
| Field, J | 1 |
| Visser, A | 1 |
| Whitbread, R | 1 |
| Tallot, M | 1 |
| Lipman, J | 1 |
| Kirkpatrick, CM | 1 |
| Martínková, J | 1 |
| Pokorná, P | 1 |
| Záhora, J | 1 |
| Chládek, J | 1 |
| Vobruba, V | 1 |
| Selke-Krulichová, I | 1 |
| Chládková, J | 1 |
| Cooper, AC | 1 |
| Finkelstein, M | 1 |
| Petejova, N | 2 |
| Zahalkova, J | 2 |
| Duricova, J | 2 |
| Kacirova, I | 2 |
| Brozmanova, H | 1 |
| Urbanek, K | 1 |
| Grundmann, M | 2 |
| Martinek, A | 2 |
| Moffett, BS | 1 |
| Rossano, JW | 1 |
| Plášek, J | 1 |
| Valkovský, I | 1 |
| Radej, J | 1 |
| Matejovic, M | 1 |
| Veinstein, A | 1 |
| Venisse, N | 1 |
| Badin, J | 1 |
| Pinsard, M | 1 |
| Robert, R | 1 |
| Dupuis, A | 1 |
| Krueger, WA | 1 |
| Lenhart, FP | 1 |
| Neeser, G | 1 |
| Ruckdeschel, G | 1 |
| Schreckhase, H | 1 |
| Eissner, HJ | 1 |
| Forst, H | 1 |
| Eckart, J | 1 |
| Peter, K | 1 |
| Unertl, KE | 1 |
| Bhatt-Mehta, V | 1 |
| Donn, SM | 1 |
| Panidis, D | 1 |
| Markantonis, SL | 1 |
| Boutzouka, E | 1 |
| Karatzas, S | 1 |
| Baltopoulos, G | 1 |
| Falagas, ME | 1 |
| Kopterides, P | 1 |
| Zarowitz, BJ | 1 |
| Robert, S | 1 |
| Mlynarek, M | 1 |
| Peterson, EL | 1 |
| Horst, HM | 1 |
| Ronchera-Oms, CL | 1 |
| Tormo, C | 1 |
| Ordovás, JP | 1 |
| Abad, J | 1 |
| Jiménez, NV | 1 |
| Bolsin, S | 1 |
| Jones, S | 1 |
| Dorman, T | 1 |
| Swoboda, S | 1 |
| Zarfeshenfard, F | 1 |
| Trentler, B | 1 |
| Lipsett, PA | 1 |
| Heslet, L | 1 |
| Tvede, M | 1 |
| Tang, GJ | 1 |
| Tang, JJ | 1 |
| Lin, BS | 1 |
| Kong, CW | 1 |
| Lee, TY | 1 |
| Barletta, JF | 1 |
| Johnson, SB | 1 |
| Nix, DE | 1 |
| Nix, LC | 1 |
| Erstad, BL | 1 |
| Hansen, M | 1 |
| Christrup, LL | 1 |
| Jarløv, JO | 1 |
| Kampmann, JP | 1 |
| Bonde, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Impact of 30 mg/kg Amikacin and 8 mg/kg Gentamicin on Serum Concentrations in Critically Ill Patients With Severe Sepsis[NCT02898961] | Phase 4 | 63 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| Population Pharmacokinetics Modeling : a Priori Optimization of Amikacin First Dose in Critically Ill Patients Using a Nomogram[NCT03683511] | 138 participants (Actual) | Observational | 2014-04-21 | Completed | |||
| Predicting Acute Kidney Injury in Infants Exposed to Nephrotoxic Drugs: A Big Data Approach to Predict NEOnatal Acute Kidney Injury in Newborns expoSed to nephroTOxic Drugs. (NeoAKI STOP)[NCT05851222] | 4,200 participants (Anticipated) | Observational | 2023-08-01 | Not yet recruiting | |||
| Pharmacokinetics of Tobramycin Administered at the Beginning of Intermittent Hemodialysis Session[NCT03904836] | Phase 1 | 11 participants (Actual) | Interventional | 2019-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for gentamicin and Critical Illness
| Article | Year |
|---|---|
Clinical Pharmacokinetics of Gentamicin in Various Patient Populations and Consequences for Optimal Dosing for Gram-Negative Infections: An Updated Review.
Topics: Adult; Aged; Anti-Bacterial Agents; Body Weight; Child; Critical Illness; Gentamicins; Humans; Infan | 2022 |
Aminoglycosides against carbapenem-resistant Enterobacteriaceae in the critically ill: the pitfalls of aminoglycoside susceptibility.
Topics: Amikacin; Anti-Bacterial Agents; Biological Availability; Carbapenem-Resistant Enterobacteriaceae; C | 2017 |
[An effect of continuous and intermittent renal replacement therapy on antibiotic treatment in critically ill patients with sepsis - a practice-based perspective of vancomycin and gentamycin therapies].
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Critical Illness; Gentamicins; Humans; Renal Dialysis; S | 2012 |
Old antibiotics for infections in critically ill patients.
Topics: Anti-Bacterial Agents; Chloramphenicol; Critical Illness; Cross Infection; Drug Resistance, Bacteria | 2007 |
Gentamicin dosing in critically ill patients.
Topics: Anti-Bacterial Agents; Critical Illness; Gentamicins; Humans | 2001 |
4 trials available for gentamicin and Critical Illness
| Article | Year |
|---|---|
Gentamicin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration (CVVHDF).
Topics: Anti-Bacterial Agents; Critical Illness; Gentamicins; Hemodiafiltration; Humans; Metabolic Clearance | 2015 |
Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr
Topics: Administration, Topical; Antibiotic Prophylaxis; APACHE; Bacterial Infections; Critical Illness; Cro | 2002 |
Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Body Fluids; Critical Illness; Female; Gentam | 2005 |
Expanded gentamicin volume of distribution in critically ill adult patients receiving total parenteral nutrition.
Topics: Adult; Aged; Anti-Bacterial Agents; Communicable Diseases; Critical Illness; Female; Fluorescence Po | 1995 |
39 other studies available for gentamicin and Critical Illness
| Article | Year |
|---|---|
Aminoglycosides' dosing and monitoring practices in critically ill patients in Quebec hospitals.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; Critical Illness; Drug Monitoring; Gentamicins; Ho | 2022 |
Hemoperfusion with Seraph 100 Microbind Affinity Blood Filter Unlikely to Require Increased Antibiotic Dosing: A Simulations Study Using a Pharmacokinetic/Pharmacodynamic Approach.
Topics: Anti-Bacterial Agents; Critical Illness; Gentamicins; Hemoperfusion; Humans; Imipenem; Meropenem; Va | 2023 |
Dose Optimization of Gentamicin in Critically Ill Neonates.
Topics: Anti-Bacterial Agents; Area Under Curve; Bayes Theorem; Birth Weight; Computer Simulation; Critical | 2020 |
Target Drug Exposure Attainment in Children: How to Get from Better to Best.
Topics: Anti-Bacterial Agents; Child; Critical Illness; Gentamicins; Humans; Infant, Newborn; Tobramycin; Va | 2020 |
External Validation of Model-Based Dosing Guidelines for Vancomycin, Gentamicin, and Tobramycin in Critically Ill Neonates and Children: A Pragmatic Two-Center Study.
Topics: Anti-Bacterial Agents; Critical Illness; Drug Monitoring; Female; Gentamicins; Humans; Infant; Infan | 2020 |
Therapeutic Drug Monitoring of Gentamicin Peak Concentrations in Critically Ill Patients.
Topics: Anti-Bacterial Agents; Critical Illness; Drug Monitoring; Female; Gentamicins; Humans; Male; Middle | 2017 |
Predictive performance of a gentamicin population pharmacokinetic model in two western populations of critically ill patients.
Topics: Acute Kidney Injury; Aged; Anti-Bacterial Agents; Area Under Curve; Critical Illness; Drug Administr | 2018 |
Pharmacokinetics of intravenous and nebulized gentamicin in critically ill patients.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchoalveolar Lavage Fluid; Critical Illness; G | 2018 |
Population Pharmacokinetics with Monte Carlo Simulations of Gentamicin in a Population of Severely Ill Adult Patients from Sub-Saharan Africa.
Topics: Adult; Africa South of the Sahara; Aged; Aged, 80 and over; Anti-Bacterial Agents; Critical Illness; | 2019 |
Dose derivation of once-daily dosing guidelines for gentamicin in critically ill pediatric patients.
Topics: Administration, Intravenous; Adolescent; Anti-Bacterial Agents; Area Under Curve; Body Weight; Child | 2014 |
Is gentamicin affecting the neuromuscular system of critically ill patients?
Topics: Anti-Bacterial Agents; Critical Illness; Gentamicins; Humans; Intensive Care Units; Muscle Weakness | 2015 |
Standard dosing of amikacin and gentamicin in critically ill patients results in variable and subtherapeutic concentrations.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Bacterial Infections; Cohort Studie | 2015 |
Variable pharmacokinetics of extended interval tobramycin or gentamicin among critically ill patients undergoing continuous venovenous hemofiltration.
Topics: Anti-Bacterial Agents; Critical Illness; Female; Gentamicins; Hemofiltration; Humans; Male; Middle A | 2015 |
Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Critic | 2016 |
Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Critic | 2016 |
Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Critic | 2016 |
Impact of 30 mg/kg amikacin and 8 mg/kg gentamicin on serum concentrations in critically ill patients with severe sepsis.
Topics: Administration, Intravenous; Adult; Aged; Aged, 80 and over; Amikacin; Anti-Bacterial Agents; Critic | 2016 |
Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models.
Topics: Animals; Anti-Infective Agents; Carbapenems; Caspofungin; Ceftriaxone; Ciprofloxacin; Critical Illne | 2015 |
Comparison of ß-lactam plus aminoglycoside versus ß-lactam plus fluoroquinolone empirical therapy in serious nosocomial infections due to Gram-negative bacilli.
Topics: Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; beta-Lactams; Cohort Studies; Critical Illness; | 2017 |
Meropenem for treating KPC-producing Klebsiella pneumoniae bloodstream infections: Should we get to the PK/PD root of the paradox?
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Bacterial Proteins; beta-Lactamases; Colistin; Critical Ill | 2017 |
Identifying High-Risk Medications Associated with Acute Kidney Injury in Critically Ill Patients: A Pharmacoepidemiologic Evaluation.
Topics: Acute Kidney Injury; Adolescent; Case-Control Studies; Child; Child, Preschool; Critical Illness; Dr | 2017 |
Acute Kidney Injury in Critically Ill Children - An Ominous Legacy.
Topics: Acute Kidney Injury; Child; Critical Illness; Gentamicins; Humans; Intensive Care Units, Pediatric | 2017 |
Determinants of gentamicin concentrations in critically ill patients: a population pharmacokinetic analysis.
Topics: Adult; Aged; Anti-Bacterial Agents; Creatinine; Critical Illness; Female; Gentamicins; Humans; Inten | 2017 |
Suboptimal aminoglycoside dosing in critically ill patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteria; Bacterial Infections; C | 2008 |
Extended-interval gentamicin: population pharmacokinetics in pediatric critical illness.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Critical Illness; Gentamicins; Humans; I | 2010 |
Gentamicin-associated acute kidney injury.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Anti-Bacterial Agents; Cohort Studies; Critical Illnes | 2009 |
Pharmacokinetics of gentamicin in critically ill patients: pilot study evaluating the first dose.
Topics: Aged; Anti-Bacterial Agents; Critical Illness; Female; Gentamicins; Humans; Male; Middle Aged; Pilot | 2010 |
Pharmacokinetic outcomes of a simplified, weight-based, extended-interval gentamicin dosing protocol in critically ill neonates.
Topics: Anti-Bacterial Agents; Birth Weight; Critical Illness; Drug Administration Schedule; Gentamicins; Ge | 2009 |
Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury.
Topics: Acute Kidney Injury; Aged; Aged, 80 and over; Critical Illness; Female; Filtration; Gentamicins; Hum | 2010 |
Tolerability and outcomes of kinetically guided therapy with gentamicin in critically ill neonates during the first week of life: an open-label, prospective study.
Topics: Anti-Bacterial Agents; Birth Weight; Critical Illness; Drug Administration Schedule; Gentamicins; Ge | 2010 |
Otoacoustic emission screen results in critically ill neonates who received gentamicin in the first week of life.
Topics: Anti-Bacterial Agents; Birth Weight; Critical Illness; Dose-Response Relationship, Drug; Drug Monito | 2011 |
Gentamicin pharmacokinetics during continuous venovenous hemofiltration in critically ill septic patients.
Topics: Acute Kidney Injury; Adult; Aged; Anti-Infective Agents; Critical Illness; Drug Monitoring; Female; | 2012 |
Use of 4-mg/kg/24-hour empiric aminoglycoside dosing in preoperative neonates with congenital heart disease.
Topics: Alprostadil; Anti-Bacterial Agents; Critical Illness; Drug Administration Schedule; Ductus Arteriosu | 2012 |
[Antimicrobial dosing in critically ill patients requiring renal replacement therapy - maximize efficacy and minimize toxicity!].
Topics: Acute Kidney Injury; Anti-Bacterial Agents; Critical Illness; Gentamicins; Humans; Renal Dialysis; S | 2012 |
Gentamicin in hemodialyzed critical care patients: early dialysis after administration of a high dose should be considered.
Topics: Anti-Bacterial Agents; Body Mass Index; Body Weight; Critical Care; Critical Illness; Drug Administr | 2013 |
Gentamicin pharmacokinetics in term newborn infants receiving high-frequency oscillatory ventilation or conventional mechanical ventilation: a case-controlled study.
Topics: Anti-Bacterial Agents; Case-Control Studies; Critical Illness; Gentamicins; High-Frequency Ventilati | 2003 |
Determination of gentamicin pharmacokinetics by bioelectrical impedance in critically ill adults.
Topics: Adult; Aged; Aged, 80 and over; Critical Illness; Electric Impedance; Female; Gentamicins; Humans; I | 1993 |
Acute renal failure potentiated by gentamicin and calcium.
Topics: Acute Kidney Injury; Calcium; Critical Illness; Drug Interactions; Gentamicins; Humans | 1997 |
Impact of altered aminoglycoside volume of distribution on the adequacy of a three milligram per kilogram loading dose. Critical Care Research Group.
Topics: Anti-Bacterial Agents; Bacterial Infections; Critical Illness; Dose-Response Relationship, Drug; Fem | 1998 |
[Inhalation of antibiotics in intensive care patients. Is pneumonia to be treated as bronchial asthma?].
Topics: Administration, Inhalation; Anti-Bacterial Agents; Critical Care; Critical Illness; Gentamicins; Hum | 1998 |
Factors affecting gentamicin pharmacokinetics in septic patients.
Topics: Aged; Analysis of Variance; Anti-Bacterial Agents; Antibiotic Prophylaxis; APACHE; Blood Urea Nitrog | 1999 |
Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens.
Topics: Adolescent; Adult; Age Factors; Aged; Anti-Bacterial Agents; Body Weight; Creatinine; Critical Illne | 2000 |